TECX Stock Overview
A clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Tectonic Therapeutic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.13 |
| 52 Week High | US$18.62 |
| 52 Week Low | US$15.00 |
| Beta | 0 |
| 11 Month Change | -4.78% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -5.17% |
Recent News & Updates
Shareholder Returns
| TECX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.3% | -0.3% | 2.6% |
| 1Y | n/a | 9.8% | 17.3% |
Return vs Industry: Insufficient data to determine how TECX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how TECX performed against the US Market.
Price Volatility
| TECX volatility | |
|---|---|
| TECX Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TECX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TECX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 45 | Alise Reicin | tectonictx.com |
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators.
Tectonic Therapeutic, Inc. Fundamentals Summary
| TECX fundamental statistics | |
|---|---|
| Market cap | US$237.66m |
| Earnings (TTM) | -US$43.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.5x
P/E RatioIs TECX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TECX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.60m |
| Earnings | -US$43.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TECX perform over the long term?
See historical performance and comparison